INTERNATIONAL CONGRESS OF
CancerGenetics
Recruiting molecular signaling pathway for Pregnancy associated breast cancer Precision medicine
-
Behnaz Habibinia,1 Flora Forouzesh,2 Fatemeh Shahriari,3 Mohammad Amin Javidi,4,*
1. Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
2. Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
3. Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
4. Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
- Introduction: Pregnancy-Associated Breast Cancer (PABC) is a rare but aggressive form of breast cancer that occurs during pregnancy or within five years postpartum. The incidence of PABC varies widely based on geographic location, diagnostic criteria, and inclusion/exclusion factors, ranging from 15 to 35 cases per 100,000 births or approximately 1 in 3,000 pregnancies. This variation highlights the importance of awareness and early detection in diverse populations.
- Methods: Gene Expression Omnibus (GEO) GSE53031,GSE31192 Scopus, Google Scholar, ResearchGate
- Results: Treatment of PABC: Surgery: Safe during pregnancy and postpartum. (Mastectomy is preferred if radiation therapy will be delayed.) Chemotherapy: Avoided during the first trimester but can be administered in the second and third trimesters. Anthracycline-based regimens are preferred. Radiation Therapy: Contraindicated during pregnancy but can be administered postpartum. Biologic and Endocrine Therapies: Typically avoided during pregnancy, but m ay be considered postpartum based on the patient’s condition Molecular Subtypes of PABC: These subtypes each present unique challenges, particularly because pregnancy and postpartum hormonal changes significantly affect breast tissue and complicate diagnosis and treatment. Gene Expression: Gene expression studies utilizing datasets GSE53031 and GSE31192 identified 239 differentially expressed genes (DEGs) in PABC, with 101 genes up-regulated. Among these, 14 hub genes were highlighted, including ASB6, which plays a significant role in regulating insulin signaling and adipocyte function. ASB6 has emerged as a potential prognostic marker and therapeutic target, influencing breast cancer progression by altering the tissue microenvironment through metabolic regulation. The integration of these findings suggests that targeting ASB6 and other hub genes could enhance precision medicine approaches for PABC, offering new avenues for treatment while improving patient outcomes. Moreover, further research into the role of these genes in postpartum breast tissue remodeling may provide insights into reducing the risk of PABC development.
- Conclusion: PABC is a rare but aggressive form of breast cancer that arises during pregnancy or the postpartum period, posing significant diagnostic and treatment challenges. Gene expression analysis has revealed 239 differentially expressed genes, including key hub genes like ASB6, CREB1, and MMP9, which contribute to the aggressive nature of PABC. ASB6, in particular, plays a critical role in regulating insulin signaling and may serve as both a biomarker and therapeutic target. Hormonal changes, immune system alterations, and incomplete breast involution during the postpartum period are believed to contribute to PABC progression, underscoring the need for precision medicine approaches. Targeting these molecular pathways offers the potential for more effective and personalized treatments, improving outcomes for PABC patients.
- Keywords: Pregnancy-Associated Breast Cancer, DEG ASB6, Molecular pathways, Gene expression
